OBJECTIVE: Bone morphogenetic protein-2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in various tumors. However, a correlation between BMP-2 expression in human gliomas and patients' prognosis has not been reported. To address this question, this study was to investigate the BMP-2 expression pattern in human gliomas and to evaluate its prognostic relevance. METHODS: We analyzed the expression of the BMP-2 antigen in a series of 98 gliomas of various grade and histology by immunohistochemistry on paraffin-embedded sections. Then, the correlation of BMP-2 expression pattern with clinical-pathological features of patients and its prognostic relevance were determined. RESULTS: Immunohistochemical analysis with anti-BMP-2 antibody revealed dense and spotty staining in the tumor cells and its expression levels became significantly higher as the gliomas' grade advanced (P < 0.001). The median survival of patients with intensively positive BMP-2 expression was significantly shorter than that with negative expression (318 vs. 1197 days, P < 0.0001). The Kaplan-Meier survival curves showed that the BMP-2 expression was not only a significant predictor of survival in high-grade gliomas (grade IV, P = 0.02), but also in lower-grade gliomas (grades II and III, P < 0.001). CONCLUSIONS: These results indicate that BMP-2 is a highly sensitive marker for gliomas prognosis and suggest that the expression level of BMP-2 may be a potent tool for the clinical prognosis of gliomas patients.
OBJECTIVE:Bone morphogenetic protein-2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in various tumors. However, a correlation between BMP-2 expression in humangliomas and patients' prognosis has not been reported. To address this question, this study was to investigate the BMP-2 expression pattern in humangliomas and to evaluate its prognostic relevance. METHODS: We analyzed the expression of the BMP-2 antigen in a series of 98 gliomas of various grade and histology by immunohistochemistry on paraffin-embedded sections. Then, the correlation of BMP-2 expression pattern with clinical-pathological features of patients and its prognostic relevance were determined. RESULTS: Immunohistochemical analysis with anti-BMP-2 antibody revealed dense and spotty staining in the tumor cells and its expression levels became significantly higher as the gliomas' grade advanced (P < 0.001). The median survival of patients with intensively positive BMP-2 expression was significantly shorter than that with negative expression (318 vs. 1197 days, P < 0.0001). The Kaplan-Meier survival curves showed that the BMP-2 expression was not only a significant predictor of survival in high-grade gliomas (grade IV, P = 0.02), but also in lower-grade gliomas (grades II and III, P < 0.001). CONCLUSIONS: These results indicate that BMP-2 is a highly sensitive marker for gliomas prognosis and suggest that the expression level of BMP-2 may be a potent tool for the clinical prognosis of gliomaspatients.
Authors: Laura D Hover; Philip Owens; Alexander L Munden; Jialiang Wang; Lola B Chambless; Corey R Hopkins; Charles C Hong; Harold L Moses; Ty W Abel Journal: Neuro Oncol Date: 2015-12-18 Impact factor: 12.300
Authors: Pilar González-Gómez; Jose Crecente-Campo; Cristina Zahonero; Maria de la Fuente; Aurelio Hernández-Laín; Helena Mira; Pilar Sánchez-Gómez; Marcos Garcia-Fuentes Journal: Oncotarget Date: 2015-05-10
Authors: Kenneth Yan; Qiulian Wu; Diana H Yan; Christine H Lee; Nasiha Rahim; Isabel Tritschler; Jennifer DeVecchio; Matthew F Kalady; Anita B Hjelmeland; Jeremy N Rich Journal: Genes Dev Date: 2014-05-01 Impact factor: 11.361
Authors: Bolesław Kuzaka; Marek Janiak; Krzysztof H Włodarski; Piotr Radziszewski; Paweł K Włodarski Journal: Arch Med Sci Date: 2015-03-18 Impact factor: 3.318